Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression

Journal of Affective Disorders

Volumn 155, Issue 1, 2014, Pages 123-129

  Shiroma, Paulo R ^a,c   Johns, Brian ^b,c   Kuskowski, Michael ^a,c   Wels, Joseph ^a   Thuras, Paul ^a,c   Albott, C Sophia ^a,c   Lim, Kelvin O ^a,c  

^a VA MEDICAL CENTER   (United States)

^b NORTH MEMORIAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Depression; Ketamine; Psychopharmacology; Treatment resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; KETAMINE; ONDANSETRON;

ADULT; AGED; ARTICLE; ASSISTED VENTILATION; CLINICAL ARTICLE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; IRRITABILITY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PERSONALITY DISORDER; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; YOUNG ADULT;

DEPRESSION; KETAMINE; PSYCHOPHARMACOLOGY; TREATMENT-RESISTANT DEPRESSION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84891852276     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2013.10.036     Document Type: Article

References (37)

1. J.A. Aldrete The post-anesthesia recovery score revisited J. Clin. Anesth. 7 1 1995 89 91
2. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 4 2000 351 354
3. A.L.M Bond The use of analogue scales in rating subjective feelings Br. J. Med. Psychol. 47 1974 211 218
4. J.D. Bremner, J.H. Krystal, F.W. Putnam, S.M. Southwick, C. Marmar, D.S. Charney, and C.M. Mazure Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) J. Trauma. Stress 11 1 1998 125 136
5. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, S. Khalife, W.A. Kammerer, Z. Quezado, D.A. Luckenbaugh, G. Salvadore, R. Machado-Vieira, H.K. Manji, and C.A. Zarate Jr A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression Arch. Gen. Psychiatry 67 8 2010 793 802
6. R.S. Duman, N. Li, R.J. Liu, V. Duric, and G. Aghajanian Signaling pathways underlying the rapid antidepressant actions of ketamine Neuropharmacology 62 1 2012 35 41
7. M.B. First, R.L. Spitzer, M. Gibbon, and J.B.W Williams Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1996 American Psychiatric Press Washington, DC
8. M.F. Folstein, S.E. Folstein, and P.R. McHugh Mini-mental state. A practical method for grading the cognitive state of patients for the clinician J. Psychiatr. Res. 12 3 1975 189 198
9. S.M. Green, and J. Li Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions Acad. Emergency Med.: Off. J. Soc. Acad. Emergency Med. 7 3 2000 278 281
10. R. Guirado, D. Sanchez-Matarredona, E. Varea, C. Crespo, J.M. Blasco-Ibanez, and J. Nacher Chronic fluoxetine treatment in middle-aged rats induces changes in the expression of plasticity-related molecules and in neurogenesis BMC Neurosci. 13 2012 5 2202-13-5
11. W. Guy ECDEU Assessment Manual for Psychopharmacology 1976 US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Rockville, MD
12. M. Hamilton A rating scale for depression J. Neurol. Neurosurg. Psychiatry 23 1960 56 62
13. L. Ibrahim, N. Diazgranados, J. Franco-Chaves, N. Brutsche, I.D. Henter, P. Kronstein, R. Moaddel, I. Wainer, D.A. Luckenbaugh, H.K. Manji, and C.A. Zarate Jr Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 37 6 2012 1526 1533
14. H. Jick, J.A. Kaye, and S.S. Jick Antidepressants and the risk of suicidal behaviors 292 3 2004 338 343 J. Am. Med. Assoc. 292 3 2004 338 343
15. E.T. Kavalali, and L.M. Monteggia Synaptic mechanisms underlying rapid antidepressantaction of ketamine Am J Psychiatry 169 11 2012 1150 1156
16. J.H. Krystal, E.B. Perry Jr, R. Gueorguieva, A. Belger, S.H. Madonick, A. Abi-Dargham, T.B. Cooper, L. Macdougall, W. Abi-Saab, and D.C. D'Souza Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function Arch. Gen. Psychiatry 62 9 2005 985 994
17. A.P. Leccese, K.L. Marquis, A. Mattia, and J.E. Moreton The anticonvulsant and behavioral effects of phencyclidine and ketamine following chronic treatment in rats Behav. Brain Res. 22 3 1986 257 264
18. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.Y. Li, G. Aghajanian, and R.S. Duman mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science (New York, N.Y.) 329 5994 2010 959 964
19. Y. Liao, J. Tang, P.R. Corlett, X. Wang, M. Yang, H. Chen, T. Liu, X. Chen, W. Hao, and P.C. Fletcher Reduced dorsal prefrontal gray matter after chronic ketamine use Biol. Psychiatry 69 1 2011 42 48
20. J.E. Malberg, A.J. Eisch, E.J. Nestler, and R.S. Duman Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus J. Neurosci.: Off. J. Soc. Neurosci. 20 24 2000 9104 9110
21. S.J. Mathew, J.W. Murrough, M. aan het Rot, K.A. Collins, D.L. Reich, and D.S. Charney Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial Int. J. Neuropsychopharmacol./Off. Sci. J. Coll. Int. Neuropsychopharmacol. (CINP) 13 1 2010 71 82
22. S. Middela, and I. Pearce Ketamine-induced vesicopathy: a literature review Int. J. Clin. Pract. 65 1 2011 27 30
23. S.A. Montgomery, and M. Asberg A new depression scale designed to be sensitive to change Br. J. Psychiatry: J. Mental Sci. 134 1979 382 389
24. J.W. Murrough, D.V. Iosifescu, L.C. Chang, R.K. Al Jurdi, C.E. Green, A.M. Perez, S. Iqbal, S. Pillemer, A. Foulkes, A. Shah, D.S. Charney, and S.J. Mathew Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial Am J Psychiatry 170 10 2013 1134 1142
25. J.W. Murrough, A.M. Perez, S. Pillemer, J. Stern, M.K. Parides, M. aan het Rot, K.A. Collins, S.J. Mathew, D.S. Charney, and D.V. Iosifescu Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression Biol. Psychiatry 74 4 2013 250 256
26. M. Nibuya, S. Morinobu, and R.S. Duman Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments J. Neurosci.: Off. J. Soc. Neurosci. 15 11 1995 7539 7547
27. M. Nibuya, E.J. Nestler, and R.S. Duman Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus J. Neurosci.: Off. J. Soc. Neurosci. 16 7 1996 2365 2372
28. J.W. Olney, J. Labruyere, G. Wang, D.F. Wozniak, M.T. Price, and M.A. Sesma NMDA antagonist neurotoxicity: mechanism and prevention Science (New York, N.Y.) 254 5037 1991 1515 1518
29. J.G., DR. Overall The brief psychiatric rating scale Psychol. Rep. 10 1962 799 812
30. K.G. Rasmussen, T.W. Lineberry, C.W. Galardy, S. Kung, M.I. Lapid, B.A. Palmer, M.J. Ritter, K.M. Schak, C.L. Sola, A.J. Hanson, and M.A. Frye Serial infusions of low-dose ketamine for major depression J Psychopharmacol 27 5 2013 444 450
31. A.J. Rush, M.H. Trivedi, J.W. Stewart, A.A. Nierenberg, M. Fava, B.T. Kurian, D. Warden, D.W. Morris, J.F. Luther, M.M. Husain, I.A. Cook, R.C. Shelton, I.M. Lesser, S.G. Kornstein, and S.R. Wisniewski Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study Am J Psychiatry 168 7 2011 689 701
32. H.A. Sackeim The definition and meaning of treatment-resistant depression J. Clin. Psychiatry 62 suppl. 16 2001 10 17
33. I. Schweitzer, and V. Tuckwell Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression Drug Saf.: Int. J. Med. Toxicol. Drug Exp. 19 6 1998 455 464
34. âD: implications for clinical practice Am. J. Psychiatry 163 1 2006 28 40
35. K. Wolff, and A.R. Winstock Ketamine: from medicine to misuse CNS Drugs 20 3 2006 199 218
36. C.A. Zarate Jr, N.E. Brutsche, L. Ibrahim, J. Franco-Chaves, N. Diazgranados, A. Cravchik, J. Selter, C.A. Marquardt, V. Liberty, and D.A. Luckenbaugh Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial Biol. Psychiatry 71 11 2012 939 946
37. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 8 2006 856 864